Brief: GeNeuro Says Novel Pre-Clinical Results Confirm Potential Of Its Novel Anti-HERV-K Antibody For Amyotrophic Lateral Sclerosis

Geneuro SA

18/10/2021 06:57

Oct 18 (Reuters) - GENEURO SA  GNRO.PA :
    * PRESENTATION AT AMERICAN NEUROLOGICAL ASSOCIATION CONGRESS
CONFIRMS POTENTIAL OF GENEURO'S NOVEL ANTI-HERV-K ANTIBODY FOR
AMYOTROPHIC LATERAL SCLEROSIS
    * DR. AVINDRA NATH PRESENTED NOVEL PRE-CLINICAL RESULTS OF
AMYOTROPHIC LATERAL SCLEROSIS (ALS) RESEARCH PROGRAM DEVELOPED
IN PARTNERSHIP WITH GENEURO
    * RESULTS SHOW IN PRE-CLINICAL MODELS OF ALS NEUROTOXIC
PROPERTIES
OF HERV-K ENV AND THERAPEUTIC POTENTIAL OF GENEURO'S ANTIBODY
DEVELOPED TO NEUTRALIZE HERV-K ENV
    * PRECLINICAL DEVELOPMENT PROGRAM COULD START CLINICAL
TRIALS AS
EARLY AS 2022

Source text for Eikon:  ID:nBw3K09MPa 
Further company coverage:  GNRO.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))